| Autor: |
Cocioabă D; Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.; Faculty of Physics, Doctoral School of Physics, University of Bucharest, 077125 Bucharest, Romania., Fonseca AI; ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal., Leonte R; Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania., Hrynchak I; ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal., Tudoroiu-Cornoiu R; Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.; Faculty of Chemical Engineering and Biotechnologies, Doctoral School of Applied Chemistry and Materials Science, National University of Science and Technology Politehnica Bucharest, 011061 Bucharest, Romania., do Carmo SJC; ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal.; Coimbra Institute for Biomedical Imaging and Translational Research, Institute for Nuclear Sciences Applied to Health (CIBIT/ICNAS), University of Coimbra, 3000-548 Coimbra, Portugal., Burghelea B; Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.; Faculty of Physics, Doctoral School of Physics, University of Bucharest, 077125 Bucharest, Romania., Băruță S; Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania., Almeida AR; ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal., Șerban R; Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.; Faculty of Biology, Doctoral School of Biology, University of Bucharest, 050095 Bucharest, Romania., Dinischiotu A; Faculty of Biology, Doctoral School of Biology, University of Bucharest, 050095 Bucharest, Romania., Abrunhosa AJ; ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal.; Coimbra Institute for Biomedical Imaging and Translational Research, Institute for Nuclear Sciences Applied to Health (CIBIT/ICNAS), University of Coimbra, 3000-548 Coimbra, Portugal., Niculae D; Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania. |
| Abstrakt: |
On the verge of a theranostic approach to personalised medicine, copper-64 is one of the emerging radioisotopes in nuclear medicine due to its exploitable nuclear and biochemical characteristics. The increased demand for copper-64 for preclinical and clinical studies has prompted the development of production routes. This research aims to compare the (p,n) reaction on nickel-64 solid versus liquid targets and evaluate the effectiveness of [ 64 Cu]CuCl 2 solutions prepared by the two routes. As new treatments for neurotensin receptor-overexpressing tumours have developed, copper-64 was used to radiolabel Neurotensin (8-13) and Neuromedin N. High-quality [ 64 Cu]CuCl 2 solutions were prepared using ACSI TR-19 and IBA Cyclone Kiube cyclotrons. The radiochemical purity after post-irradiation processing reached 99% (LT) and 99.99% (ST), respectively. The irradiation of a solid target with 11.8 MeV protons and 150 μAh led to 704 ± 84 MBq/μA (17.6 ± 2.1 GBq/batch at EOB). At the end of the purification process (1 h, 90.90% activity yield), the solution for peptide radiolabelling had a radioactive concentration of 1340.4 ± 70.1 MBq/mL (n.d.c.). The irradiation of a liquid target with 16.9 MeV protons and 230 μAh resulted in 3.7 ± 0.2 GBq/batch at EOB, which corresponds to an experimental production yield of 6.89 GBq.cm3/(g.µA) sat . Benefiting from a shorter purification process (40 min), the activity yielded 90.87%, while the radioactive concentration of the radiolabelling solution was lower (492 MBq/mL, n.d.c.). The [ 64 Cu]CuCl 2 solutions were successfully used for the radiolabelling of DOTA-NT(8-13) and DOTA-NN neuropeptides, resulting in a high RCP (>99%) and high molar activity (27.2 and 26.4 GBq/μmol for LT route compared to 45 and 52 GBq/μmol for ST route, respectively). The strong interaction between the [ 64 Cu]Cu-DOTA-NT(8-13) and the colon cancerous cell lines HT29 and HCT116 proved that the specificity for NTR had not been altered, as shown by the uptake and retention data. |
